Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection.

Clin Pharmacol Ther · 2022 · PMC9349574 · PMID 35797235

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Participants with higher weight or BMI showed a trend of lower concentrations for both i.m. and i.v. administration; participants weighing < 75 kg or with a BMI of < 30 kg/m 2 tended to have higher exposure.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.